Brain Tumours

Study Objectives • Determine the recommended pediatric phase 2 dose (<18 years) – Maximum tolerated dose, or if not seen – Similar steady-state systemic exposure to adults (AUC, 4000–5500 ng  h/mL) • Assess dabrafenib safety and efficacy in pediatric population

107